Chemours annual ebitda
2013
2014
2015
2022
2023
2024
2025
Chemours EBITDA Growth & History (CC)
Chemours's calculated EBITDA was $332.0M for fiscal 2025.
View full Chemours company overviewChemours annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $332.0M | −$329.0M | −49.77% |
| 2024 | 2024-12-31 | $661.0M | $462.0M | +232.16% |
| 2023 | 2023-12-31 | $199.0M | −$996.0M | −83.35% |
| 2022 | 2022-12-31 | $1.20B | — | — |
| 2015 | 2015-12-31 | $4.90B | −$943.0M | −16.15% |
| 2014 | 2014-12-31 | $5.84B | −$346.0M | −5.59% |
| 2013 | 2013-12-31 | $6.19B | — | — |
Chemours quarterly ebitda
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $147.0M | $236.0M | — |
| Q1 2026 | 2026-03-31 | $126.0M | — | — |
| Q4 2025 | 2025-12-31 | $82.0M | — | — |
| Q3 2025 | 2025-09-30 | $198.0M | — | — |
| Q2 2025 | 2025-06-30 | −$89.0M | — | — |
| Q3 2016 | 2016-09-30 | $1.24B | $72.0M | +6.14% |
| Q2 2016 | 2016-06-30 | $1.20B | −$132.0M | −9.92% |
| Q1 2016 | 2016-03-31 | $1.19B | −$47.0M | −3.80% |
| Q4 2015 | 2015-12-31 | $1.16B | — | — |
| Q3 2015 | 2015-09-30 | $1.17B | −$309.0M | −20.86% |
| Q2 2015 | 2015-06-30 | $1.33B | −$175.0M | −11.63% |
| Q1 2015 | 2015-03-31 | $1.24B | — | — |
| Q3 2014 | 2014-09-30 | $1.48B | — | — |
| Q2 2014 | 2014-06-30 | $1.50B | — | — |
Chemours ebitda trends
Between the periods ended 2013-12-31 and 2025-12-31, Chemours's ebitda decreased from $6.19B to $332.0M, a change of −$5.85B. The latest reported quarter, Q2 2026, shows $147.0M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemours source filings ↗Community posts
Chemours, DuPont and Corteva agree to a $455 million PFAS settlement
Chemours ($CC), DuPont ($DD) and Corteva ($CTVA) reached an agreement to resolve PFAS-related claims brought by North Carolina and 11 local government entities. The settlement provides for $455 million in nominal payments over 15 years. Che ...